German Health Ministry Proposes Expanded Health Data Use and Vaccine Price Regulation to Stabilize Insurance Costs

The German Federal Ministry of Health (BMG) is advancing two significant health policy initiatives aimed at improving healthcare outcomes and curbing insurance costs. First, a draft law would enable statutory health insurance companies (Krankenkassen) to collect and access extensive health data on insured individuals, including from electronic patient records. This initiative allows anonymization and processing of social and personal data, with specific attention to preventive health aspects such as herbal remedy usage and lifestyle factors, provided insured consent is obtained. An experimental clause introduces 'real laboratories' to pilot innovative data handling methods under strict oversight, addressing current legal uncertainties in health data use.

Simultaneously, the Finance Commission for Health, appointed by Health Minister Nina Warken, has recommended regulating vaccine prices within the statutory health insurance system. Their report highlights a steep rise in vaccine costs, noting that prices surged from 34.05 euros to 58.83 euros per daily therapy dose between 2019 and 2024, with the Shingrix vaccine alone increasing by 140% since 2020. Price regulation measures could save the health insurance funds up to one billion euros by 2030, aiding in stabilizing contribution rates. While experts like Charité's Leif Erik Sander endorse these proposals, concerns remain about potential impacts on pharmaceutical innovation and supply security. The pharma industry has criticized the savings strategies, urging reforms targeting systemic inefficiencies instead.

These two developments reflect concerted efforts by German policymakers to leverage data-driven prevention and cost control to enhance the sustainability of the public health insurance system.